Prospective evaluation of vitamin E for hot flashes in breast cancer survivors

被引:265
作者
Barton, DL
Loprinzi, CL
Quella, SK
Sloan, JA
Veeder, MH
Egner, JR
Fidler, P
Stella, PJ
Swan, DK
Vaught, NL
Novotny, P
机构
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] Carle Canc Ctr, Community Clin Oncol Program, Urbana, IL USA
[3] Illinois Oncol Res Assoc, Community Clin Oncol Program, Peoria, IL USA
[4] Missouri Valley Canc Consortium, Omaha, NE USA
[5] Ann Arbor Reg Community Clin Oncol Program, Ann Arbor, MI USA
[6] Duluth Community Clin Oncol Program, Duluth, MN USA
[7] Siouxland Hematol Oncol Associates, Sioux City, IA USA
关键词
D O I
10.1200/JCO.1998.16.2.495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Hot flashes represent a substantial clinical problem for some breast cancer survivors. Although estrogen or progesterone preparations can alleviate these symptoms in many patients, concern remains regarding the use of hormonal preparations in such women. Thus, there is a perceived need for nonhormonal treatments for hot flashes for breast cancer survivors. Based on anecdotal evidence that vitamin E was helpful, we designed a trial to investigate this matter. Methods: We developed and conducted a placebo-controlled, randomised, crossover trial where, after a 1 week baseline period, patients received 4 weeks of vitamin E 800 IU daily, then 4 weeks of an identical-appearing placebo, or vice versa. Diaries were used to measure potential toxicities and hot flashes during the baseline week and the two subsequent 4-week treatment periods. Results: The 120 patients evaluated for toxicity failed to show any. The 105 patients who finished the first treatment period showed a similar reduction in hot flash frequencies (25% v 22%; P = .90) for the two study arms. A crossover analysis, however, showed that vitamin E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P less than or equal to .05). At the study end, patients did not prefer vitamin 8 over the placebo (32% v 29%, respectively). Conclusion: Although this trial was able to show a statistically significant hot flash reduction with vitamin E compared to a placebo, the clinical magnitude of this reduction was marginal. (C) 1998 by American Society of Clinical Oncology.
引用
收藏
页码:495 / 500
页数:6
相关论文
共 24 条
  • [1] EFFECT OF BELLERGAL RETARD ON CLIMACTERIC COMPLAINTS - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    BERGMANS, MGM
    MERKUS, JMWM
    CORBEY, RS
    SCHELLEKENS, LA
    UBACHS, JMH
    [J]. MATURITAS, 1987, 9 (03) : 227 - 234
  • [2] Bider D, 1989, Obstet Gynecol Surv, V44, P495, DOI 10.1097/00006254-198907000-00002
  • [3] NEUROENDOCRINOLOGY OF MENOPAUSAL FLUSHES - AN HYPOTHESIS OF FLUSH MECHANISM
    CASPER, RF
    YEN, SSC
    [J]. CLINICAL ENDOCRINOLOGY, 1985, 22 (03) : 293 - 312
  • [4] CHRISTY CJ, 1945, AM J OBSTET GYNECOL, V50, P84
  • [5] PREVALENCE OF MENOPAUSAL SYMPTOMS AMONG WOMEN WITH A HISTORY OF BREAST-CANCER AND ATTITUDES TOWARD ESTROGEN REPLACEMENT THERAPY
    COUZI, RJ
    HELZLSOUER, KJ
    FETTING, JH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) : 2737 - 2744
  • [6] Cutick R, 1984, JOGN Nurs, V13, p68s
  • [7] THE EFFECT OF VITAMIN-E IN THE MENOPAUSE
    FINKLER, RS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY, 1949, 9 (01) : 89 - 94
  • [8] A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS
    FISHER, B
    COSTANTINO, J
    REDMOND, C
    POISSON, R
    BOWMAN, D
    COUTURE, J
    DIMITROV, NV
    WOLMARK, N
    WICKERHAM, DL
    FISHER, ER
    MARGOLESE, R
    ROBIDOUX, A
    SHIBATA, H
    TERZ, J
    PATERSON, AHG
    FELDMAN, MI
    FARRAR, W
    EVANS, J
    LICKLEY, HL
    KETNER, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) : 479 - 484
  • [9] FISHER B, 1992, P ANN M AM ASS CANC, V33, pA567
  • [10] GANONG W, 1993, REV MED PHYSL, P384